Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress

Citation metadata

Publisher: National Academy of Sciences
Document Type: Author abstract; Report
Length: 175 words

Document controls

Main content

Abstract :

Activating K-RAS mutations are the most frequent oncogenic mutations in human cancer. Numerous downstream signaling pathways have been shown to be deregulated by oncogenic K-ras. However, to date there are still no effective targeted therapies for this genetically defined subset of patients. Here we report the results of a small molecule, synthetic lethal screen using mouse embryonic fibroblasts derived from a mouse model harboring a conditional oncogenic [K-ras.sup.G12D] allele. Among the 50,000 compounds screened, we identified a class of drugs with selective activity against oncogenic K-ras-expressing cells. The most potent member of this class, lanperisone, acts by inducing nonapoptotic cell death in a cell cycle- and translation-independent manner. The mechanism of cell killing involves the induction of reactive oxygen species that are inefficiently scavenged in K-ras mutant cells, leading to oxidative stress and cell death. In mice, treatment with lanperisone suppresses the growth of K-ras-driven tumors without overt toxicity. Our findings establish the specific antitumor activity of lanperisone and reveal oxidative stress pathways as potential targets in Ras-mediated malignancies. targeted therapy | synthetic lethality doi/10.1073/pnas.1105941108

Source Citation

Source Citation   

Gale Document Number: GALE|A258356808